Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
ABT Price Action
Last 7 days
0.7%
Last 30 days
-1.5%
Last 90 days
1.5%
Trailing 12 Months
23.4%
ABT Stock Price
ABT RSI Chart
ABT Valuation
ABT Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
ABT Fundamentals
ABT Revenue
ABT Earnings
ABT Profitability
ABT Investor Care
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
Medical Devices
| |||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 42.3B | 0 | 0 | 0 |
| 2024 | 40.3B | 40.7B | 41.2B | 42.0B |
| 2023 | 41.5B | 40.2B | 40.0B | 40.1B |
| 2022 | 44.5B | 45.5B | 45.0B | 43.7B |
| 2021 | 37.3B | 40.2B | 42.3B | 43.1B |
| 2020 | 32.1B | 31.4B | 32.2B | 34.6B |
| 2019 | 30.7B | 30.9B | 31.4B | 31.9B |
| 2018 | 28.4B | 29.6B | 30.4B | 30.6B |
| 2017 | 22.3B | 23.6B | 25.1B | 27.4B |
| 2016 | 20.4B | 20.6B | 20.7B | 20.9B |
| 2015 | 20.4B | 20.5B | 20.6B | 20.4B |
| 2014 | 19.6B | 19.7B | 20.0B | 20.2B |
| 2013 | 21.1B | 20.7B | 20.2B | 19.7B |
| 2012 | 35.1B | 30.8B | 26.2B | 21.5B |
| 2011 | 36.5B | 37.3B | 38.4B | 38.9B |
| 2010 | 31.7B | 33.1B | 34.0B | 35.2B |
| 2009 | 29.5B | 29.7B | 29.9B | 30.8B |
| 2008 | 26.8B | 27.7B | 28.6B | 29.5B |
| 2007 | 0 | 0 | 0 | 25.9B |
Get all data in R, Python etc through our Historical Stock Data APIs
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
| CEO | Mr. Robert B. Ford |
|---|---|
| WEBSITE | abbott.com |
| SECTOR | Healthcare |
| INDUSTRY | Medical Devices |
| EMPLOYEES | 65535 |
